Clinical trial
Evaluate the Immunogenicity & Safety of GSK Biologicals' HPV Vaccine in Female…
NCT00290277 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00290277 |
|---|---|
| Title | Evaluate the Immunogenicity & Safety of GSK Biologicals' HPV Vaccine in Female Subjects Aged 10-14 Years |
| Official title | Evaluate the Immunogenicity & Safety of GSK Biologicals' HPV-16/18 L1/AS04 Vaccine Administered Intramuscularly According to a 0,1,6 Mth Schedule in Healthy Female Subjects Aged 10-14 Yrs |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Infections, Papillomavirus |
| Intervention type | Biological |
| Interventions | HPV-16/18 L1/AS04 |
| Enrollment | 300 |
| Start date | Nov 1, 2005 |
| Completion | Aug 1, 2006 |
| First posted | Feb 13, 2006 |
| Last update posted | Sep 28, 2016 |
| Countries | South Korea |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: